Naltrexone Implants — CPB 0878 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, reaffirmed its position that naltrexone implants are experimental and investigational across all indications under CPB 0878, effective January 5, 2026. No coverage path exists for this delivery format — not for opioid dependence, not for alcohol use disorder, not for anything on the list.

If your practice has been submitting claims for naltrexone implant procedures hoping for a coverage exception, this update closes that door firmly. Here's what billing teams need to know.

Quick-Reference Table

Aetna Naltrexone Implant Coverage Criteria and Medical Necessity Requirements 2026

The Aetna naltrexone implant coverage policy under CPB 0878 is unambiguous: there are no covered indications. Aetna does not recognize naltrexone implants as meeting medical necessity standards for any condition. The policy cites insufficient evidence in peer-reviewed published medical literature and states that the safety and effectiveness of naltrexone implants have not been established.

This is a blanket experimental designation — not a case-by-case prior authorization decision. You won't get coverage by documenting more thoroughly or submitting a stronger prior auth request. The coverage policy itself forecloses reimbursement regardless of diagnosis.

One critical carve-out you need to internalize: this policy does not apply to Vivitrol injections billed under HCPCS J2315, or to other commercially available naltrexone formulations that aren't implants. If your practice bills J2315 for Vivitrol, CPB 0878 doesn't touch those claims. The implant-specific restriction is exactly that — specific to the implant delivery format.

The distinction matters. A patient with an F11.20 opioid dependence diagnosis may qualify for coverage of oral naltrexone or Vivitrol under a different policy framework. The same patient getting a naltrexone implant gets a denial under CPB 0878. Same drug, same diagnosis, different delivery mechanism — and Aetna draws a hard line there.

Aetna Naltrexone Implant Exclusions and Non-Covered Indications

Every indication listed in CPB 0878 carries an experimental, investigational, or unproven designation. There are no exceptions, no tiered criteria, and no pathway to medical necessity approval. The nine named indications represent common clinical scenarios where providers have tried to use naltrexone implants — and where Aetna has explicitly rejected coverage.

The list includes conditions spanning addiction medicine, behavioral health, neurology, and endocrinology. That breadth signals that Aetna has reviewed multiple clinical contexts and reached the same conclusion each time: the evidence isn't there to support coverage.

Here's what that looks like in practice. A patient with F10.20 alcohol dependence gets the same denial outcome as a patient with F15.10 stimulant abuse or a patient with an autism spectrum disorder diagnosis. The diagnosis changes the ICD-10 code on the claim. The denial outcome doesn't change.

Providers billing for naltrexone implant procedures — whether the procedure involves surgical insertion, removal, or management — should expect claim denial across this entire diagnosis range.

Coverage Indications at a Glance

Note: Specific ICD-10 codes listed below reflect codes confirmed in the source data provided for this review. Where codes are not confirmed, readers are directed to the full CPB 0878 policy document. See the disclaimer in the code table section for additional context.

Note: Vivitrol injections billed under J2315 are outside the scope of this policy. The exclusions above apply specifically to implant delivery formats.

Aetna Naltrexone Implant Billing Guidelines and Action Items 2026

This policy is active as of January 5, 2026. If your practice performs naltrexone implant procedures and bills Aetna, act now.

CPT, HCPCS, and ICD-10 Codes for Naltrexone Implants Under CPB 0878

The policy data does not list specific CPT or HCPCS procedure codes for the implant delivery and removal services themselves. Aetna's CPB 0878 addresses the coverage classification — experimental across all indications — without enumerating the specific procedure codes used to bill implant insertion or removal. Your billing team should work with your compliance officer to identify the unlisted or miscellaneous codes your practice uses for these procedures and apply the non-coverage designation accordingly.

The one HCPCS code explicitly carved out from this policy is J2315 (Vivitrol injection, naltrexone, extended-release injectable suspension). That code is out of scope for CPB 0878 and governed by a separate coverage policy.

Key ICD-10-CM Diagnosis Codes Under CPB 0878

These codes reflect diagnoses confirmed in the source data reviewed for this article. All carry experimental / non-covered status when paired with naltrexone implant procedures. The full policy includes 134 ICD-10-CM codes — review the complete CPB 0878 document at Aetna's clinical policy library for the full list before updating your billing guidelines.

Disclaimer: Subcategory descriptions below are drawn from the ICD-10-CM code set and are not reproduced verbatim from CPB 0878. Verify against the full policy document.

The policy data notes 134 total ICD-10-CM codes in scope. The full code set extends beyond what is reproduced above. Review the complete CPB 0878 policy document at Aetna's clinical policy library for the full list before updating your billing guidelines.